NanoString Technologies Inc. Launches Commercial Reagents To Enable Laboratories To Rapidly Develop Tests From Translational Research Discoveries

SEATTLE & SAN FRANCISCO--(BUSINESS WIRE)--NanoString Technologies, Inc. (NASDAQ: NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced the global commercial launch of the nCounter Elements™ General Purpose Reagents (GPRs), a solution that enables clinical laboratories to independently develop multiplexed genomic assays and then rapidly translate those assays into clinical diagnostics as Laboratory Developed Tests (LDTs). The announcement, made at the 21st International Molecular Medicine Tri-Conference (TRI-CON) taking place in San Francisco, February 9 – 14, marks the conclusion of a successful early access program that involved 22 participants from five countries in North America, Europe, and Asia.

Help employers find you! Check out all the jobs and post your resume.